These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9648714)

  • 61. [Treatment of refractory immunological diseases by applying new biological preparations: an overview].
    Imai K; Takahashi H
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):1-6. PubMed ID: 15045809
    [No Abstract]   [Full Text] [Related]  

  • 62. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
    Gupta S; DeAngelo J; Melamed I; Walter JE; Kobayashi AL; Bridges T; Sublett JW; Bernstein JA; Koterba A; Manning M; Maltese J; Hoeller S; Turpel-Kantor E; Kreuwel H; Kobayashi RH
    J Clin Immunol; 2023 Aug; 43(6):1414-1425. PubMed ID: 37160610
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
    Santamaria M; Neth O; Douglass JA; Krivan G; Kobbe R; Bernatowska E; Grigoriadou S; Bethune C; Chandra A; Horneff G; Borte M; Sonnenschein A; Kralickova P; Ramón SS; Langguth D; Gonzalez-Granado LI; Alsina L; Querolt M; Griffin R; Hames C; Mondou E; Price J; Sanz A; Lin J
    J Clin Immunol; 2022 Apr; 42(3):500-511. PubMed ID: 34973143
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
    Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
    J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.
    Borte M; Pac M; Serban M; Gonzalez-Quevedo T; Grimbacher B; Jolles S; Zenker O; Neufang-Hueber J; Belohradsky B
    J Clin Immunol; 2011 Oct; 31(5):752-61. PubMed ID: 21674136
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.
    Chouksey A; Duff K; Wasserbauer N; Berger M
    Allergy Asthma Clin Immunol; 2005 Sep; 1(3):120-30. PubMed ID: 20529223
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
    Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
    J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.
    Skoda-Smith S; Torgerson TR; Ochs HD
    Ther Clin Risk Manag; 2010 Feb; 6():1-10. PubMed ID: 20169031
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunoglobulin replacement therapy in children.
    Garcia-Lloret M; McGhee S; Chatila TA
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):833-49, ix. PubMed ID: 18940577
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
    Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M
    J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.
    Nicolay U; Kiessling P; Berger M; Gupta S; Yel L; Roifman CM; Gardulf A; Eichmann F; Haag S; Massion C; Ochs HD
    J Clin Immunol; 2006 Jan; 26(1):65-72. PubMed ID: 16418804
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical immunology in practice, new opportunities.
    Stein MR
    Clin Rev Allergy Immunol; 2004 Oct; 27(2):83-91. PubMed ID: 15576892
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.
    Berger M
    Curr Allergy Asthma Rep; 2002 Sep; 2(5):368-78. PubMed ID: 12165202
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
    Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
    J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies.
    Meth MJ; Rosenthal DW; Bonagura VR
    Ann Allergy Asthma Immunol; 2010 Aug; 105(2):187-8. PubMed ID: 20674834
    [No Abstract]   [Full Text] [Related]  

  • 76. Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
    Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD
    Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases.
    Bal K; Kałuzińska-Parzyszek I; Sobocińska A; Podlecka D; Jerzyńska J; Stelmach I
    Indian J Pediatr; 2015 Aug; 82(8):768-9. PubMed ID: 25786586
    [No Abstract]   [Full Text] [Related]  

  • 78. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product.
    Stiehm ER; Casillas AM; Finkelstein JZ; Gallagher KT; Groncy PM; Kobayashi RH; Oleske JM; Roberts RL; Sandberg ET; Wakim ME
    J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):848-9. PubMed ID: 9648714
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.